Aerie Pharmaceuticals, Inc. (NASDAQ:AERI)‘s stock had its “buy” rating reiterated by investment analysts at Needham & Company LLC in a research note issued on Sunday. They presently have a $65.00 price target on the stock. Needham & Company LLC’s price objective suggests a potential upside of 11.49% from the company’s current price.

AERI has been the subject of a number of other research reports. Cowen and Company set a $100.00 price target on shares of Aerie Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, May 26th. Canaccord Genuity set a $65.00 price objective on shares of Aerie Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, August 16th. Cantor Fitzgerald restated an “overweight” rating and set a $62.00 price objective (up previously from $56.00) on shares of Aerie Pharmaceuticals in a research report on Thursday, July 20th. BidaskClub downgraded shares of Aerie Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Saturday, June 17th. Finally, Stifel Nicolaus restated a “buy” rating on shares of Aerie Pharmaceuticals in a research report on Friday, May 26th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and twelve have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $66.36.

Aerie Pharmaceuticals (NASDAQ:AERI) opened at 58.30 on Friday. The firm’s 50-day moving average is $54.57 and its 200-day moving average is $49.84. The firm’s market cap is $2.12 billion. Aerie Pharmaceuticals has a 52 week low of $32.05 and a 52 week high of $60.15.

Aerie Pharmaceuticals (NASDAQ:AERI) last issued its quarterly earnings results on Tuesday, August 1st. The company reported ($0.82) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.84) by $0.02. On average, equities analysts anticipate that Aerie Pharmaceuticals will post ($2.59) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This story was posted by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of US and international trademark and copyright law. The legal version of this story can be read at https://www.americanbankingnews.com/2017/09/17/aerie-pharmaceuticals-inc-aeri-rating-reiterated-by-needham-company-llc.html.

Institutional investors and hedge funds have recently made changes to their positions in the business. Quantbot Technologies LP acquired a new position in Aerie Pharmaceuticals in the 1st quarter valued at $107,000. Ameritas Investment Partners Inc. acquired a new position in Aerie Pharmaceuticals in the 1st quarter valued at $108,000. BNP Paribas Arbitrage SA increased its stake in Aerie Pharmaceuticals by 2,711.4% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 3,711 shares of the company’s stock valued at $195,000 after buying an additional 3,579 shares during the period. Amalgamated Bank acquired a new position in Aerie Pharmaceuticals in the 2nd quarter valued at $204,000. Finally, Palisade Capital Management LLC NJ acquired a new position in Aerie Pharmaceuticals in the 2nd quarter valued at $212,000. 94.64% of the stock is currently owned by institutional investors.

About Aerie Pharmaceuticals

Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).

Analyst Recommendations for Aerie Pharmaceuticals (NASDAQ:AERI)

Receive News & Ratings for Aerie Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.